188 related articles for article (PubMed ID: 17693000)
1. Construction and biological characterization of artificial recombinants between a wild type flavivirus (Kunjin) and a live chimeric flavivirus vaccine (ChimeriVax-JE).
Pugachev KV; Schwaiger J; Brown N; Zhang ZX; Catalan J; Mitchell FS; Ocran SW; Rumyantsev AA; Khromykh AA; Monath TP; Guirakhoo F
Vaccine; 2007 Sep; 25(37-38):6661-71. PubMed ID: 17693000
[TBL] [Abstract][Full Text] [Related]
2. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses.
Guy B; Guirakhoo F; Barban V; Higgs S; Monath TP; Lang J
Vaccine; 2010 Jan; 28(3):632-49. PubMed ID: 19808029
[TBL] [Abstract][Full Text] [Related]
3. Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: infant mice provide an accurate surrogate for the test in monkeys.
Monath TP; Myers GA; Beck RA; Knauber M; Scappaticci K; Pullano T; Archambault WT; Catalan J; Miller C; Zhang ZX; Shin S; Pugachev K; Draper K; Levenbook IS; Guirakhoo F
Biologicals; 2005 Sep; 33(3):131-44. PubMed ID: 15975826
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis.
Guirakhoo F; Zhang ZX; Chambers TJ; Delagrave S; Arroyo J; Barrett AD; Monath TP
Virology; 1999 May; 257(2):363-72. PubMed ID: 10329547
[TBL] [Abstract][Full Text] [Related]
5. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
[TBL] [Abstract][Full Text] [Related]
6. Replication of chimeric yellow fever virus-dengue serotype 1-4 virus vaccine strains in dendritic and hepatic cells.
Brandler S; Brown N; Ermak TH; Mitchell F; Parsons M; Zhang Z; Lang J; Monath TP; Guirakhoo F
Am J Trop Med Hyg; 2005 Jan; 72(1):74-81. PubMed ID: 15728870
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the replication kinetics of the ChimeriVax-DEN 1, 2, 3, 4 tetravalent virus mixture in Aedes aegypti by real-time reverse transcriptase-polymerase chain reaction.
Johnson BW; Chambers TV; Crabtree MB; Guirakhoo F; Monath TP; Miller BR
Am J Trop Med Hyg; 2004 Jan; 70(1):89-97. PubMed ID: 14971704
[TBL] [Abstract][Full Text] [Related]
8. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.
Monath TP; Soike K; Levenbook I; Zhang ZX; Arroyo J; Delagrave S; Myers G; Barrett AD; Shope RE; Ratterree M; Chambers TJ; Guirakhoo F
Vaccine; 1999 Apr; 17(15-16):1869-82. PubMed ID: 10217584
[TBL] [Abstract][Full Text] [Related]
9. A single amino acid substitution in the West Nile virus nonstructural protein NS2A disables its ability to inhibit alpha/beta interferon induction and attenuates virus virulence in mice.
Liu WJ; Wang XJ; Clark DC; Lobigs M; Hall RA; Khromykh AA
J Virol; 2006 Mar; 80(5):2396-404. PubMed ID: 16474146
[TBL] [Abstract][Full Text] [Related]
10. Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys.
Monath TP; Levenbook I; Soike K; Zhang ZX; Ratterree M; Draper K; Barrett AD; Nichols R; Weltzin R; Arroyo J; Guirakhoo F
J Virol; 2000 Feb; 74(4):1742-51. PubMed ID: 10644345
[TBL] [Abstract][Full Text] [Related]
11. Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE).
Arroyo J; Guirakhoo F; Fenner S; Zhang ZX; Monath TP; Chambers TJ
J Virol; 2001 Jan; 75(2):934-42. PubMed ID: 11134306
[TBL] [Abstract][Full Text] [Related]
12. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates.
Guirakhoo F; Pugachev K; Arroyo J; Miller C; Zhang ZX; Weltzin R; Georgakopoulos K; Catalan J; Ocran S; Draper K; Monath TP
Virology; 2002 Jun; 298(1):146-59. PubMed ID: 12093182
[TBL] [Abstract][Full Text] [Related]
13. Single mutation in the flavivirus envelope protein hinge region increases neurovirulence for mice and monkeys but decreases viscerotropism for monkeys: relevance to development and safety testing of live, attenuated vaccines.
Monath TP; Arroyo J; Levenbook I; Zhang ZX; Catalan J; Draper K; Guirakhoo F
J Virol; 2002 Feb; 76(4):1932-43. PubMed ID: 11799188
[TBL] [Abstract][Full Text] [Related]
14. Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis.
Lai CJ; Monath TP
Adv Virus Res; 2003; 61():469-509. PubMed ID: 14714441
[TBL] [Abstract][Full Text] [Related]
15. Safety of an attenuated West Nile virus vaccine, live Flavivirus chimera in horses.
Long MT; Gibbs EP; Mellencamp MW; Zhang S; Barnett DC; Seino KK; Beachboard SE; Humphrey PP
Equine Vet J; 2007 Nov; 39(6):486-90. PubMed ID: 18065304
[TBL] [Abstract][Full Text] [Related]
16. A single M protein mutation affects the acid inactivation threshold and growth kinetics of a chimeric flavivirus.
Maier CC; Delagrave S; Zhang ZX; Brown N; Monath TP; Pugachev KV; Guirakhoo F
Virology; 2007 Jun; 362(2):468-74. PubMed ID: 17303204
[TBL] [Abstract][Full Text] [Related]
17. Infectious cDNA clone of attenuated Langat tick-borne flavivirus (strain E5) and a 3' deletion mutant constructed from it exhibit decreased neuroinvasiveness in immunodeficient mice.
Pletnev AG
Virology; 2001 Apr; 282(2):288-300. PubMed ID: 11289811
[TBL] [Abstract][Full Text] [Related]
18. Construction and biological properties of yellow fever 17D/dengue type 1 recombinant virus.
Mateu GP; Marchevsky RS; Liprandi F; Bonaldo MC; Coutinho ES; Dieudonné M; Caride E; Jabor AV; Freire MS; Galler R
Trans R Soc Trop Med Hyg; 2007 Mar; 101(3):289-98. PubMed ID: 17169387
[TBL] [Abstract][Full Text] [Related]
19. A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys.
Guirakhoo F; Zhang Z; Myers G; Johnson BW; Pugachev K; Nichols R; Brown N; Levenbook I; Draper K; Cyrek S; Lang J; Fournier C; Barrere B; Delagrave S; Monath TP
J Virol; 2004 Sep; 78(18):9998-10008. PubMed ID: 15331733
[TBL] [Abstract][Full Text] [Related]
20. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections.
Monath TP; McCarthy K; Bedford P; Johnson CT; Nichols R; Yoksan S; Marchesani R; Knauber M; Wells KH; Arroyo J; Guirakhoo F
Vaccine; 2002 Jan; 20(7-8):1004-18. PubMed ID: 11803060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
